August 2024 - HempWire

ThursdayAug 29, 2024 10:30 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

INM-901 oral formulation shows encouraging results in preclinical studies High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will…

ThursdayAug 29, 2024 10:00 am

Medical Marijuana, Intoxicating Hemp Products Go Head to Head in Mississippi

In 2020, 69% of voters in the state of Mississippi passed a medical cannabis initiative, but the Supreme Court of the state nullified the measure. Two years later, the legislature approved the Mississippi Medical Cannabis Act, allowing the establishment of a high-quality, regulated industry. Less than a year later, more than 20,000 residents in the state were benefitting from the program. Medical cannabis production in the state is strictly regulated, with all growers having to apply for permits before they can commence their operations. Every plant is also tracked from the time it hits six inches in height through maturity…

TuesdayAug 27, 2024 10:00 am

Businesses Complain That Illicit Hemp Intoxicants Undercut Medical Cannabis

Earlier this week, the Medical Marijuana Oversight Committee in South Dakota held a meeting during which the state’s director of Public Health Laboratory along with business owners discussed how illegal hemp intoxicants were affecting the state’s medical cannabis industry. In particular, these parties are concerned about the proliferation of synthetically modified products derived from hemp and are being sold as delta-8 and delta-10 THC. These compounds induce a high similar to cannabis. Similar to cannabis, these synthetic products are in form of pre-rolled joints, smokable flower, edibles and vape oil. Unlike cannabis, however, the companies that produce these products aren’t…

MondayAug 26, 2024 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market

Lexaria, a global innovator in drug delivery platforms, just reported positive results from its applied research program conducted in collaboration with the National Research Council of Canada (“NRC”) The study’s objective was to examine the molecular properties of semaglutide, processed with its patented DehydraTECH(TM) technology, comparing it to Rybelsus(R), the commercially available alternative Lexaria’s DehydraTECH demonstrated that semaglutide can be efficiently released in a simulated gastric fluid environment, without the use of salcaprozate sodium (“SNAC”) ingredient chemistry This milestone moves the company closer to the diabetes treatment market, projected to hit $153.98 billion in value by 2032 Lexaria Bioscience (NASDAQ:…

MondayAug 26, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

A long-term preclinical study of Alzheimer's Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer's Disease, and INM-901-treated Alzheimer's Disease at two dosing levels The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes…

ThursdayAug 22, 2024 10:00 am

California Senate Scuttles Bill Seeking to Restrict Hemp Intoxicants

Products derived from hemp and synthetic cannabinoids have proliferated in markets across the country, with states such as South Dakota, Iowa and Louisiana moving to ban them. In California, however, players in the industry are championing for a different approach. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, suggested a regulation path that involved stricter manufacturing and labeling practices. Miller added that there was also a need to keep these products away from children. This comes as the California Senate rejected a legislation this week that would impose strict regulations on intoxicating cannabinoids derived from hemp. This decision by…

TuesdayAug 20, 2024 2:15 pm

Hemp Industry Says Missouri Governor ‘Overreached’ When Banning Hemp Intoxicants

Earlier this month, Missouri governor Mike Parson signed an executive order outlawing intoxicating hemp products and imposing penalties for any establishment that sells food products or a state liquor license found selling these products. The order also prohibits companies such as Mighty Kind Co. from producing THC beverages derived from hemp in the state. Mighty Kind Co. manufactures different kinds of hemp seltzers. Prior to this order, hemp drinks were permitted for sale in the state outside of licensed marijuana dispensaries following the passage of the 2018 Farm Bill. The executive order signed by Governor Parson takes effect on Sept.…

FridayAug 16, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting Oral GLP-1 Alternatives for Diabetes and Obesity Treatment

Lexaria, a global innovator in drug delivery platforms, is exploring its patented DehydraTECH(TM) technology for the oral delivery of glucagon-like peptide-1 (“GLP-1”) drugs. GLP-1 drugs have shown great promise in addressing diabetes and obesity, with nearly all the major brands administered only through injection devices. A previous human study by Lexaria evidenced improved bioavailability when semaglutide was administered orally, as compared to standard Rybelsus®. Lexaria has several additional R&D studies underway, including both animal and human investigations into semaglutide, liraglutide and tirzepatide. Together, those three drugs represent more than 90% of all revenue in the current global GLP1 market. Data…

ThursdayAug 15, 2024 10:00 am

Hempseed Meal Gets Nod for Inclusion in Layer Feed

During its annual meeting in San Antonia last week, the Association of American Feed Control Officials announced its approval to use hempseed meal in chicken feed for commercial layers. Hempseed meal is made by milling or grinding leftover cake after oil is extracted from Cannabis sativa L. seeds via mechanical processing. This decision will allow this hemp ingredient to be used as a source of fat and protein in diets for layers in America, with the agency capping the ingredient’s rate of inclusion at 20%. The agency is now planning to include hempseed meal, albeit tentatively, in its official publication.…

TuesdayAug 13, 2024 10:00 am

USDA Beefs Up Trade Committee to Promote US Hemp Internationally

The Office of the U.S. Trade Representative (USTR) and the U.S. Department of Agriculture have appointed a new individual to the Agricultural Technical Advisory Committee for Trade in Tobacco, Cotton, Peanuts and Hemp. Prior to its name change in 2023, the committee’s name didn’t include hemp. The first individuals appointed to represent the hemp industry to this committee served on the Agricultural Technical Advisory Committee for Trade in Tobacco, Cotton and Peanuts. USTR representative Katherine Tai and secretary of agriculture Tom Vilsack made the announcement of the new appointment last week, revealing that the VP of Government Affairs for Lazarus…

News and publishing service for hemp related companies

Contact us: 303.498.7722

Month: August 2024